A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis

Herrera, María Inés; Kölliker-Frers, Rodolfo; Otero‐Losada, Matilde; Lloret, Santiago Pérez; Filippo, Macarena; Tau, Julia; Capani, Francisco; Villa, Andrés

doi:10.3389/fneur.2019.01046

Cited by 11 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herrera et al also showed increased NF-H concentrations in patients with 5 year RRMS evolution. In their study, a correlation between NF-H levels and disease progression was observed, which suggested its potential reliability in monitoring the clinical condition of RRMS patients [39]. Shehab et al obtained similar results.…”

Section: Heavy Neurofilament (Nf-h)mentioning

confidence: 67%

The Comparison of the Selected Parameters of Brain Injury and Interleukins in the CSF in Patients Diagnosed De Novo with RRMS Compared to the Control Group

Adamczyk,

Morawiec,

Mamak

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system (CNS). Due to the different phenotypes of the disease and non-specific symptoms of MS, there is a great need for a validated panel of biomarkers to facilitate the diagnosis, predict disease progression, and evaluate treatment outcomes. Methods: We determined the levels of the parameters of brain injury (NF-H, GPAF, S100B, and UCHL1) and the selected cytokines in the cerebrospinal fluid (CSF) in 101 patients diagnosed de novo with RRMS and 75 healthy controls. All determinations were made using the Bio-Plex method. Results: We found higher levels of NF-H and GFAP in the relapsing-remitting multiple sclerosis (RRMS) group compared to the controls. The concentrations of both molecules were significantly increased in patients with Gd+ lesions on brain MRI. The level of S100B did not differ significantly between the groups. UCHL1 concentrations were higher in the control group. We found some correlations between the selected cytokines, the levels of the parameters of brain injury, and the time from the first symptoms to the diagnosis of MS. Conclusions: The role of the above molecules in MS is promising. However, further research is warranted to define their precise functions.

show abstract

Section: Heavy Neurofilament (Nf-h)mentioning

confidence: 67%

The Comparison of the Selected Parameters of Brain Injury and Interleukins in the CSF in Patients Diagnosed De Novo with RRMS Compared to the Control Group

Adamczyk,

Morawiec,

Mamak

et al. 2023

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Interestingly, despite a higher increase observed in CSF NfH than in NfL levels during disease activity NfL still proved to be a more reliable marker for disease stability 340 . Higher NfH levels were also associated with relapse activity 340,358 , EDSS 359 and MSSS 360 scores and T2 lesion volume 360 . These findings are refuted by other studies which failed to demonstrate a correlation between NfH levels and clinical and MRI variables of MS patients 315,324 .…”

Section: Neurofilament Heavy Chain In Msmentioning

confidence: 98%

Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: a Comprehensive Review of the Literature with a Focus on Neurofilaments and Therapeutic Considerations

Biernacki¹,

Kokas²,

Sandi³

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: multiple sclerosis (MS) is the most common immune-mediated chronic neurodegenerative disease of the central nervous system (CNS), affecting young people. Due to the permanent disability, cognitive impairment, and the enormous detrimental impact MS can exert on the patients’ health-related quality of life. It is of great importance to recognise it in time and commence adequate treatment at an early stage. The currently used disease-modifying therapies (DMT) aim to reduce disease activity and thus halt disability development, which in current clinical practice are monitored by clinical and imaging parameters but not by biomarkers found in blood and/or the cerebrospinal fluid (CSF). Both clinical and radiological measures routinely used to monitor disease activity lack information on the fundamental pathophysiological features and mechanisms of MS. Furthermore, they lag behind the disease process itself. By the time a clinical relapse becomes evident or a new lesion appears on the MRI scan, potentially irreversible damage has already occurred in the CNS. In recent years several biomarkers that previously have been linked to other neurological and immunological diseases have received increased attention in MS. Additionally, other novel, potential biomarkers with prognostic and diagnostic properties have been detected in the CSF and blood of MS patients. Areas covered: in this review, we summarise the most up to date knowledge and research conducted on the already known and most promising new biomarker candidates found in the CSF and blood of MS patients. Author commentary: the current diagnostic criteria of MS rely on three pillars; MRI imaging, clinical events and the presence of oligoclonal bands in the CSF (which was reinstated into the diagnostic criteria by the most recent revision). Even though the most recent McDonald criteria made the diagnosis of MS faster than the prior iteration, it is still not an infallible diagnostic toolset, especially at the very early stage of clinically isolated syndrome. Together with the gold standard MRI and clinical measures, ancillary blood and CSF biomarkers may not just improve diagnostic accuracy and speed but very well may become agents to monitor therapeutic efficacy and make even more personalised treatment in MS a reality in the near future. The major disadvantage of these biomarkers in the past has been the need to obtain CSF to measure them. However, the recent advances in extremely sensitive immunoassays made their measurement possible from peripheral blood even when present only in minuscule concentrations. This should mark the beginning of a new biomarker research and utilisation era in MS.

show abstract

“…The neurofilament heavy chain (NfH) is an essential component of the neuronal cytoskeleton. It is highly expressed in large-caliber axons, playing a critical role in maintaining the axonal structural integrity, and can be used to indicate the extent of neuro-axonal damage ( Petzold et al, 2016 ; Herrera et al, 2019 ). NfH levels in the CSF were related to the clinical severity of MS and neurodegeneration in MRI ( Khalil et al, 2013 ; Petzold et al, 2016 ).…”

Section: Potential Biochemical Neurodegeneration Markers Associated W...mentioning

confidence: 99%

Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review

Pogoda-Wesołowska,

Dziedzic,

Maciak

et al. 2023

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Approximately 70% of relapsing-remitting multiple sclerosis (RRMS) patients will develop secondary progressive multiple sclerosis (SPMS) within 10–15 years. This progression is characterized by a gradual decline in neurological functionality and increasing limitations of daily activities. Growing evidence suggests that both inflammation and neurodegeneration are associated with various pathological processes throughout the development of MS; therefore, to delay disease progression, it is critical to initiate disease-modifying therapy as soon as it is diagnosed. Currently, a diagnosis of SPMS requires a retrospective assessment of physical disability exacerbation, usually over the previous 6–12 months, which results in a delay of up to 3 years. Hence, there is a need to identify reliable and objective biomarkers for predicting and defining SPMS conversion. This review presents current knowledge of such biomarkers in the context of neurodegeneration associated with MS, and SPMS conversion.

show abstract

A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis

Cited by 11 publications

References 17 publications

The Comparison of the Selected Parameters of Brain Injury and Interleukins in the CSF in Patients Diagnosed De Novo with RRMS Compared to the Control Group

The Comparison of the Selected Parameters of Brain Injury and Interleukins in the CSF in Patients Diagnosed De Novo with RRMS Compared to the Control Group

Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: a Comprehensive Review of the Literature with a Focus on Neurofilaments and Therapeutic Considerations

Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review

Contact Info

Product

Resources

About